Health Care · Health Care Equipment · US stock · price as of 22 Oct 2026
Key indicators
Price
$102.51
52-week range
$81.97 – $132.03
Market cap
$179.1B
P/E (trailing)
28.6×
EV / EBITDA
26.7×
Free-cash-flow yield
4.1%
Dividend yield
2.5%
Revenue (last 12 months)
$45.1B
Revenue growth (3y a year)
0.5%
Operating margin
17.1%
Return on invested capital
7.5%
Net debt / EBITDA
3.5×
Fair value
Fair value (average of valid models)$91.74 middle half of models $86 – $104
Versus priceFair−11% to fair value
P/E multiple
$103.23
P/B multiple
$125.20
P/S multiple
$107.40
EV/EBITDA multiple
$94.28
EV/EBIT multiple
$105.61
EV/revenue multiple
$102.82
10-year DCF, EBITDA exit
$86.08
5-year DCF, EBITDA exit
$96.26
10-year DCF, revenue exit
$86.00
5-year DCF, revenue exit
$96.47
10-year DCF, growth exit
$42.31
5-year DCF, growth exit
$43.55
Dividend discount, stable
$86.10
Dividend discount, multi-stage
$134.05
Earnings power value
$66.78
Model uncertainty
High
X-Ray Score
41/ 100 · High confidence · ahead of 23% of sector peers
Valuation35
Growth37
Profitability42
Financial health42
Dividends59
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
Abbott Laboratories is a diversified health care company whose products cover medical devices, diagnostics, nutrition and established pharmaceuticals. Its range includes diabetes monitoring sensors, heart and neuromodulation devices, laboratory and point-of-care testing systems, and nutritional products such as Similac and Ensure. Customers include hospitals, clinicians, laboratories, retailers and consumers in markets around the world.
Revenue comes from a broad mix of device, diagnostic, nutrition and pharmaceutical products. It totals $45.1 billion over the last twelve months, with growth of 0.5% a year across the last three years. The operating margin is 17.1%, and the business earns a profit of 8% on the capital invested in it. Abbott carries net debt of 3.5 times EBITDA, and the dividend yield is 2.5%.
StocksXray gives Abbott Laboratories an X-Ray Score of 41 out of 100 (high confidence), ahead of 23% of the S&P 500 stocks in its sector. Its strongest lens is dividends (59) and its weakest is valuation (35).
Our fair value (the average of the valid models) is $91.74 (range $86.04 to $104.42). At $102.51 the stock trades 12% above that value, so the label is "Fair" with high model uncertainty. Fair value is a range, not a price target.
XStocksXray
Abbott Laboratories (ABT)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2021
FY2022
FY2023
FY2024
FY2025
Now
Price
$127.41
$101.06
$103.34
$108.31
$122.25
$102.51
Market cap
$227.9B
$178.3B
$180.7B
$189.3B
$213.7B
$179.1B
P/E
32.3×
25.8×
31.7×
14.2×
32.9×
28.6×
EV / revenue
5.5×
4.2×
4.7×
4.7×
4.9×
4.6×
EV / EBITDA
28.0×
22.1×
29.1×
28.7×
27.1×
26.8×
Price / free cash flow
26.4×
22.8×
35.7×
29.8×
28.9×
24.3×
Free-cash-flow yield
3.8%
4.4%
2.8%
3.4%
3.5%
4.1%
Price / book
6.4×
4.9×
4.7×
4.0×
4.1×
3.4×
Dividend yield
–
1.90%
2.01%
2.07%
1.96%
2.46%
Fundamentals checklist ● 1 Good · ● 9 Average · ● 6 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−2.9%Average
Free-cash-flow yield4.1%Average
Risk models
Altman Z score3.3×Average
Piotroski F-Score6 of 9Average
Growth
EPS growth (3y)−1.6%Bad
Free-cash-flow growth (3y)−1.8%Average
Revenue growth (3y)0.5%Bad
Growth consistency100%Good
Balance sheet
Current ratio1.4×Average
Net debt / EBITDA3.5×Bad
Interest cover14.4×Average
Valuation
Fair value vs price0.9×Bad
EBIT / EV yield3.7%Average
Profitability
Return on invested capital7.5%Bad
Operating margin17.1%Average
Gross profitability23.0%Bad
XStocksXray
Abbott Laboratories (ABT)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY21
FY22
FY23
FY24
FY25
LTM
Revenue
43,075
43,653
40,109
41,950
44,328
45,134
Gross profit
24,538
24,511
22,134
23,244
25,009
25,393
Operating income
8,425
8,362
6,478
6,825
8,053
7,705
Net income
7,071
6,933
5,723
13,402
6,524
6,276
Diluted EPS ($)
3.94
3.91
3.26
7.64
3.72
3.59
Free cash flow
8,648
7,804
5,059
6,351
7,395
7,378
Gross margin
57.0%
56.1%
55.2%
55.4%
56.4%
56.3%
Operating margin
19.6%
19.2%
16.2%
16.3%
18.2%
17.1%
Net margin
16.4%
15.9%
14.3%
31.9%
14.7%
13.9%
Balance sheet
FY21
FY22
FY23
FY24
FY25
LTM
Total assets
75,196
74,438
73,214
81,414
86,713
110,429
Cash
9,799
9,882
6,896
7,616
8,522
6,803
Total debt
18,050
16,773
14,679
14,125
12,929
34,047
Equity
35,802
36,686
38,603
47,664
52,130
52,061
Dividend per share ($)
–
1.92
2.08
2.24
2.40
2.44
Revenue and net income US$ billions: navy revenue, teal net income
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value is the average of up to 15 valuation models, most of them anchored to the company's own multiples, so it stays near the price and should be read as a range, not a point. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.
